GlassScriptPhysician profile
Andrew R John
NPI 1609193614
$2,503.55
in general payments reported to CMS, 2019-2025
22 companies · $717 in 2025
The $717 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $33.19 · 2021: $39.38 · 2022: $452 · 2023: $403 · 2024: $480 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,528 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.00 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $390.89 | 2024-2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $277.57 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $262.91 | 2022-2024 | Sotyktu |
| Janssen Biotech, INC. | $247.48 | 2019-2025 | Tremfya |
| Amgen INC. | $208.36 | 2022-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $161.60 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $154.39 | 2022 | |
| Sun Pharmaceutical Industries INC. | $117.78 | 2019-2024 | |
| Incyte Corporation | $115.20 | 2022-2025 | Opzelura |
| Genzyme Corporation | $114.00 | 2022-2025 | |
| Lilly USA, LLC | $79.92 | 2021-2025 | Ebglyss |
| Abbvie INC. | $77.23 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $72.89 | 2019-2025 | |
| Organogenesis INC. | $49.36 | 2024-2025 | Nushield |
| Regeneron Healthcare Solutions, INC. | $39.87 | 2025 | Dupixent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $25.88 | 2024 | |
| Kyowa Kirin, INC. | $23.50 | 2023 | Poteligeo |
| Dermavant Sciences, INC. | $22.72 | 2023 | Vtama |
| Prugen, INC. Pharmaceuticals | $17.77 | 2019 | |
| Genentech USA, INC. | $16.49 | 2023 | Xolair |
| Organon LLC | $15.24 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.